Trinity Biotech Plc
Research Trinity Biotech Plc (TRIB) on Bullrun: market cap USD 196.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTRIB
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 196.64M
- Financial periodQ4 2025
- RevenueUSD 43.79M
- Net income-USD 37.38M
- Free cash flow-USD 12.15M
- Gross margin38.6%
Valuation Snapshot
latest market cap is USD 196.64M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | USD 61.56M | -USD 31.79M | -USD 14.26M | 34.8% | -2.82 | USD 5.17M | USD 100.76M | -USD 35.18M |
| FY2023 | USD 56.83M | -USD 24.02M | n/a | 34.2% | -17.6 | USD 3.69M | USD 67.43M | -USD 23.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 196.64M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.72M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 15.80M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 16.43M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 37.73M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 29.89M | 3.7 | n/a | n/a |
About Trinity Biotech Plc
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Trinity Biotech Plc's market cap?
Trinity Biotech Plc's market capitalization is USD 196.64M.
What does Trinity Biotech Plc do?
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe.